SEC Form 3 · accession 0001104659-15-045756
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Evan Loh
Director
Period of report
Jun 16, 2015
Accepted (ET)
Jun 16, 2015 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,163 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.363 | holding | — | — | — | — | Dec 4, 2022 | Common Stock | 1,730 | — | D |
| Stock Option (Right to Buy)F2 | $4.565 | holding | — | — | — | — | Feb 10, 2025 | Common Stock | 11,768 | — | D |
Explanation of responses
- F1The options vest and become exercisable over a four-year period, with 25% vesting on the first anniversary of the grant date (December 4, 2013) and 1/48th of the options vesting monthly thereafter.
- F2The options vest and become exercisable over a four-year period, with 25% vesting on the first anniversary of the grant date (February 10, 2016) and 1/48th of the options vesting monthly thereafter.
Remarks
Exhibit List: Exhibit 24.1 - Power of Attorney